Clinical trials: Skin Testing
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT02993159
- Testing
- Afimoxifene, Laboratory Biomarker Analysis, Tamoxifen Citrate
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University
Nevi
Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
This project is a multicenter study in which we will investigate a dual concept of nevogenesis. Study location is the Department of Dermatology at the Medical University of Graz in collaboration with centers in Austria (Vienna)…
- Trial name
- NCT00422448
- Testing
- To test the frequency of BRAF and NRAS mutations among nevi
- Where
- Austria
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Healthy
Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation
Validate the performance of Philips FAST SpO2 with Masimo Pulse Oximetry Sensors in determining functional arterial oxygen saturation (SpO2) using arterial saturation (SaO2) as a reference in the range of 70-100% in subjects of…
- Trial name
- NCT06148623
- Testing
- Philips FAST SpO2 with Masimo Pulse Oximetry Sensors
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Hidradenitis Suppurativa
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS.
- Trial name
- NCT05819398
- Testing
- Spesolimab i.v., Spesolimab s.c.
- Where
- 162 sites in United States, Argentina and 33 more
- Volunteers
- 209 people
- Sponsor
- Boehringer Ingelheim
Allergic Skin Reaction
Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers using an intradermal skin test.
- Trial name
- H001-A2 (NCT01689363)
- Testing
- Hyaluronidase, Histamine, Saline
- Where
- 5 sites in United States
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Leprosy
Leprosy Skin Test Antigens Trial
The purpose of this study is to see how healthy people and leprosy patients react to 2 new skin tests for detecting leprosy. The study will evaluate the new skin tests that may aid in measuring the number of people exposed to…
- Trial name
- NCT00128193
- Testing
- Tuberculin, Purified Protein Derivative, MLSA-LAM, MLCwA
- Where
- 6 sites in United States, Nepal
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Hyperpigmentation
An 18-week Study to Evaluate a Test Product With a Marketed Prescription Product
The purpose of this study is to assess the efficacy (ability to produce a desired or intended result) of a topical product (applied to the skin) to improve skin lightness, skin condition and appearance (hyperpigmentation [dark…
- Trial name
- NCT07136766
- Testing
- Facial Toner
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Good Molecules, LLC
Melanoma
Utility of Novel BRAF Test for Melanoma
This primary purpose of this study is to obtain blood samples from participants with both early and later stages of melanoma (Stage II/III and Stage IV).
- Trial name
- NCT01840527
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video
Genetic counseling and testing (GCT) provides invaluable information for women who are at-risk of hereditary breast and/or ovarian cancer (HBOC). Black women underutilize GCT compared to White women.
- Trial name
- NCT04476654
- Testing
- YouTube Video Arm
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer
Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
The goal of this clinical research study is to learn if metformin can help to control nerve damage (loss of motor or sensory function) that may be caused by treatment with paclitaxel in patients with breast cancer.
- Trial name
- NCT02360059
- Testing
- Metformin, Questionnaires, Sensory and Fine-Motor Tests
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Scleroderma, Systemic
A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
The main objective is to assess the potential influence of continuous intake of nintedanib on the systemic exposure of ethinylestradiol and levonorgestrel when administered in combination.
- Trial name
- NCT03675581
- Testing
- Microgynon, Nintedanib
- Where
- 10 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Part I was a double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LDE225 (a specific…
- Trial name
- NCT00961896
- Testing
- Vehicle, LDE225 0.25%, LDE225 0.75%
- Where
- 3 sites in Austria, Switzerland
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Actinic Keratosis
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.
- Trial name
- NCT02616601
- Testing
- Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
- Where
- 17 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Advanced Solid Tumor
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: Pembrolizumab AMG386
- Trial name
- NCT03239145
- Testing
- Pembrolizumab, Trebananib
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Psoriasis
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03835481
- Testing
- BI 730357
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 165 people
- Sponsor
- Boehringer Ingelheim
Erythema, Sensitisation
Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
The primary objective of this study was to assess the sensitization potential of Omeza Collagen Matrix compared to that of a negative control based on a Modified Human Repeat Insult Patch Test.
- Trial name
- NCT04510675
- Testing
- Test Article, Negative Control
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Omeza, LLC
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Netherton Syndrome
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older.
- Trial name
- NCT05856526
- Testing
- Spesolimab - solution for infusion, Spesolimab - solution for injection
- Where
- 28 sites in United States, Australia and 12 more
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Dermal Irritation
14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
to determine the ability of the test article to cause irritation to the skin of humans under controlled patch test conditions
- Trial name
- NCT02737618
- Testing
- Trojan "Chameleon" Personal Lubricant
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.